A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric and Gastroesophageal Junction Adenocarcinoma Clinical Trial

Official title:
A Randomized, Double-blind, Phase 3 Study Of Cadonilimab (AK104) Plus Pulocimab (AK109) And Paclitaxel Versus Paclitaxel In Patients With Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma Who Failed First-line Immunochemotherapy

Status Not yet recruiting

Clinical Trial Summary

This randomized, multicenter, double-blind, phase 3 study will evaluate the efficacy and safety of the combination of cadonilimab (AK104) and pulocimab (AK109) and paclitaxel compared with paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma who failed first-line immunochemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Adenocarcinoma
Esophageal Neoplasms
Gastric and Gastroesophageal Junction Adenocarcinoma

Clinical Trial Details

NCT number	NCT06341335
Study type	Interventional
Source	Akeso
Contact	Ting Liu
Phone	+86(0760)8987 3999
Email	clinicaltrials@akesobio.com
Status	Not yet recruiting
Phase	Phase 3
Start date	May 2024
Completion date	July 2027

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05383482` - Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1	Phase 1/Phase 2
Terminated	`NCT04260191` - Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 1
Not yet recruiting	`NCT05508737` - Phase II Study of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) With Previously Treated Advanced Gastric Cancer	Phase 1/Phase 2